Therapeutic Methods Using Antibody Drug Conjugates (ADCs)
Summary
The European Patent Office published patent application EP3801635A2 by Regeneron Pharmaceuticals covering therapeutic methods using Antibody Drug Conjugates (ADCs) for cancer (A61P 35/00) and immune disorders (A61P 37/00). The patent designates all EU member states including Germany, France, UK, Italy, Spain, and others. This IP protection covers ADC methods linked to A61K 47/68 and C07K 16/28 classifications.
What changed
The European Patent Office granted patent application EP3801635A2 to Regeneron Pharmaceuticals covering therapeutic methods using Antibody Drug Conjugates. The patent claims methods for treating cancer (A61P 35/00) and immune disorders (A61P 37/00) using ADCs linked to antigens recognized by C07K 16/28 antibodies. Protection extends to designated contracting states across the EU.
Pharmaceutical and biotechnology companies developing ADC-based therapeutics should review this patent to assess potential freedom-to-operate implications. Regeneron now holds IP protection for these therapeutic methods in European markets, which may affect licensing strategies and competitive development of similar ADC technologies for oncology and immunology applications.
What to do next
- Monitor for patent prosecution updates in specific countries
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
THERAPEUTIC METHODS USING ANTIBODY DRUG CONJUGATES (ADCS)
Publication EP3801635A2 Kind: A2 Apr 01, 2026
Applicants
Regeneron Pharmaceuticals, Inc.
Inventors
BOITANO, Anthony, COOKE, Michael, PROCTOR, Jennifer Lynn, MCDONAGH, Charlotte Fenton
IPC Classifications
A61K 47/68 20170101AFI20220302BHEP C07K 16/28 20060101ALI20220302BHEP A61K 39/395 20060101ALI20220302BHEP A61K 39/00 20060101ALI20220302BHEP A61K 35/00 20060101ALI20220302BHEP A61P 35/00 20060101ALI20220302BHEP A61P 37/00 20060101ALI20220302BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for EPO Patent Bulletin - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Therapeutics (A61P) publishes new changes.